Replimune Group, Inc. (REPL) News
Follow Replimune Group, Inc. (REPL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 41 public stories across 22 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
REPL reports fiscal 2026 first-half net loss
Net loss attributable to shareholders increased 25.27% year over year. Basic EPS was negative.
EARNINGS | Oct 29, 2026, 03:05 AM UTC
M
Replimune Shares Fall More Than 2% After Narrower Fiscal Q2 Net Loss
Replimune shares were down more than 2% after the company posted a narrower fiscal second-quarter net loss.
EQUITY | Oct 28, 2026, 01:43 PM UTC
M
Replimune Group Reports Quarterly Results for Period Ended September 30
EQUITY | Oct 28, 2026, 01:34 PM UTC
M
Replimune Reports Fiscal Q2 2027 Net Loss of $57.1 Million
The company reported a $57.1 million net loss for the quarter ended September 30, 2026, compared with $83.1 million a year earlier. Cash and cash equivalents totaled $307.8 million at quarter-end.
EQUITY | Oct 28, 2026, 11:31 AM UTC
M
Replimune Q2 Loss Narrows as Expenses Fall
EQUITY | Oct 28, 2026, 11:24 AM UTC
M
Replimune Schedules Oct. 28 Call to Discuss Fiscal Q2 2027 Results
Replimune will host the call at 8:00 a.m. ET and provide a replay on its investor website.
EQUITY | Oct 22, 2026, 12:04 PM UTC
L
REPL: All proposals, including auditor ratification and share increase, were approved by stockholders
The meeting established a quorum, introduced key officers, and presented three proposals: auditor ratification, executive compensation, and an increase in authorized shares. All proposals were approved by stockholders, a
EQUITY | Sep 15, 2026, 01:03 PM UTC
L
REPL: All proposals, including share increase and auditor ratification, were approved
The meeting established a quorum and addressed key proposals, including auditor ratification, executive compensation, and an increase in authorized shares. All proposals were approved by stockholders.Based on Replimune G
EQUITY | Sep 15, 2026, 12:53 PM UTC
L
REPL: TujuCare launches with targeted rollout, strong operational prep, and promising clinical pipeline
TujuCare's commercial launch is on track, focusing on 200 experienced academic centers with full team onboarding and robust operational readiness. Early revenues will reflect initial dosing, with acceleration expected as
EQUITY | Sep 10, 2026, 02:19 PM UTC
L
Replimune to present at Cantor Global Healthcare Conference 2026 fireside chat
Replimune Group says members of its management team will take part in a fireside chat at the Cantor Global Healthcare Conference 2026.
EQUITY | Sep 03, 2026, 12:08 PM UTC
L
Replimune to present at the Cantor Global Healthcare Conference 2026
Replimune said it will present at the Cantor Global Healthcare Conference 2026.
EQUITY | Sep 03, 2026, 12:01 PM UTC
L
Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today?
Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today?
EQUITY | Aug 27, 2026, 03:14 AM UTC
L
Replimune Group Is Maintained at Overweight by JP Morgan
Replimune Group Is Maintained at Overweight by JP Morgan
EQUITY | Aug 26, 2026, 01:49 PM UTC
L
REPL - Robbins LLP Urges REPL Investors Who Lost Money Investing in Replimune to Contact the Firm for Information About Leading the Class Ac
REPL - Robbins LLP Urges REPL Investors Who Lost Money Investing in Replimune to Contact the Firm for Information About Leading the Class Action
EQUITY | Aug 21, 2026, 08:20 PM UTC
L
Replimune announces inducement grants under Nasdaq Rule 5635(c)(4)
Replimune (REPL) announces inducement grants under Nasdaq Listing Rule 5635(c)(4).
REGULATION | Aug 19, 2026, 08:01 PM UTC
L
REPL reports EPS of $(0.72) and $69.8M net loss
REPL reported EPS of $(0.72) versus $(0.95) YoY, net loss of $69.8M versus $86.7M YoY, and R&D expenses of $49.3M versus $57.8M YoY.
EARNINGS | Aug 14, 2026, 12:03 PM UTC
L
Replimune reports Fiscal Q1 2027 financial results
Replimune (REPL) reports its Fiscal First Quarter 2027 financial results and provides a corporate update, according to TradeXchange Newsdesk.
EARNINGS | Aug 14, 2026, 12:00 PM UTC
L
Replimune Group shareholders face Oct. 5, 2026 lead plaintiff deadline
Replimune Group, Inc. (REPL) faces a lead plaintiff deadline of October 5, 2026 in a lawsuit, according to a reminder issued to shareholders.
REGULATION | Aug 13, 2026, 04:37 PM UTC
L
REPL - Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma
REPL - Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen
REGULATION | Aug 06, 2026, 08:00 PM UTC
H
Leerink Upgrades Replimune To Outperform
Leerink upgrades Replimune to Outperform
EQUITY | Aug 04, 2026, 12:14 PM UTC
H
REPL upgraded to Outperform
REPL upgraded to Outperform at Leerink
EQUITY | Aug 04, 2026, 10:18 AM UTC
H
Replimune Upgraded to Outperform by Leerink
Leerink upgrades Replimune to Outperform
EQUITY | Aug 04, 2026, 09:48 AM UTC
H
IOVA falls 8.4% on REPL melanoma treatment
IOVA shares drop on competing treatment news
EQUITY | Jul 31, 2026, 02:38 PM UTC
H
Wedbush Upgrades REPL to Outperform
Wedbush upgrades REPL to Outperform
EQUITY | Jul 31, 2026, 01:01 PM UTC
L
REPL upgraded from Neutral to Overweight @ Cantor
REPL upgraded from Neutral to Overweight @ Cantor
EQUITY | Jul 31, 2026, 11:44 AM UTC
H
Banks Upgrade AXTI, IP, PLXS, SAIA
Banks upgrade multiple stocks
EQUITY | Jul 31, 2026, 11:38 AM UTC
H
Premarket Gainers: WETO +226.33%
WETO leads premarket gainers
EQUITY | Jul 31, 2026, 11:25 AM UTC
L
REPL shares surge 137% premarket after the FDA's panel of outside advisers voted to back results from a trial studying the company's drug fo
REPL shares surge 137% premarket after the FDA's panel of outside advisers voted to back results from a trial studying the company's drug for a type of skin cancer. REPL seeks accelerated approval for RP1 in combination
REGULATION | Jul 31, 2026, 10:52 AM UTC
H
Why Amazon Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Shares of Amazon.com Inc (NASDAQ: AMZN ) rose sharply in pre-market trading after the company posted upbeat financial results for the second quarter. Amazon reported second-quarter revenue of $200.61 billion, beating the
EARNINGS | Jul 31, 2026, 08:50 AM UTC
L
REPL - Replimune Announces Favorable Outcome of FDA 's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced M
REPL - Replimune Announces Favorable Outcome of FDA 's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma
REGULATION | Jul 30, 2026, 10:15 PM UTC
H
REPL Gets 10-3 Vote
REPL gets approval recommendation
EQUITY | Jul 30, 2026, 08:54 PM UTC
L
BMO sees 'uphill battle' for Replimune at Thursday's FDA panel meeting
BMO Capital analyst Evan...
REGULATION | Jul 28, 2026, 02:58 PM UTC
L
Replimune sinks after FDA briefing documents question RP1 data
Shares of Replimune are...
EQUITY | Jul 28, 2026, 02:52 PM UTC
L
REPL -21% premarket after FDA headlines
REPL -21% premarket after FDA headlines
REGULATION | Jul 28, 2026, 11:44 AM UTC
L
REPL FDA staff reviewers Flag concerns regarding Replimune's cancer drug trial ahead of July 30 advisory committee meeting - briefing docs
REPL FDA staff reviewers Flag concerns regarding Replimune's cancer drug trial ahead of July 30 advisory committee meeting - briefing docs
REGULATION | Jul 28, 2026, 11:41 AM UTC
H
Replimune Group put volume heavy and directionally bearish
Bearish flow noted in Replimune Group with 2,615 puts trading, or 1.8x expected. Most active are Aug-26 7 puts and 8/7 weekly 15 calls, with total volume in those strikes near 2,200 contracts. The Put/Call Ratio is 1.67,
EQUITY | Jul 08, 2026, 04:35 PM UTC
H
Replimune Group put volume heavy and directionally bearish
Bearish flow noted in Replimune Group with 5,913 puts trading, or 3x expected. Most active are 8/14 weekly 8 puts and 8/7 weekly 8 puts, with total volume in those strikes near 2,600 contracts. The Put/Call Ratio is 4.37
EARNINGS | Jul 07, 2026, 07:15 PM UTC
L
Wedbush Maintains Neutral on Replimune Group, Raises Price Target to $9
Wedbush analyst Robert Driscoll maintains Replimune Group (NASDAQ: REPL ) with a Neutral and raises the price target from $6 to $9.
EQUITY | Jun 30, 2026, 12:51 PM UTC
M
CAPR Falls 13%
Capricor Therapeutics stock is trading lower after the FDA plans to convene an advisory committee meeting to discuss the company's Biologics License Application for Deramiocel
EQUITY | Jun 26, 2026, 06:06 PM UTC
H
Replimune Group Says FDA Accepts Resubmission Of BLA For RP1 In Combination With Nivolumab For Advanced Melanoma, With August 2 Goal Date An
Replimune Group, Inc. (NASDAQ: REPL ), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, announced today that the U.S. Food and Drug Administration (FDA) has accepted f
MACRO | Jun 26, 2026, 12:00 PM UTC
H
RGNX: FDA Reconsiders Gene Therapy
Regenxbio aligns with FDA on next steps for potential accelerated approval of Navsunli gene therapy
EQUITY | Jun 22, 2026, 01:23 PM UTC